Summit presents Phase 3 lung cancer data beating Merck's Keytruda
A few months after Summit Therapeutics shocked the oncology world with an early claim that its lung cancer drug ivonescimab had beaten Merck’s Keytruda, it has backed up its talk with data. In the...
View ArticleEli Lilly invests in Superluminal's $120M Series A round as AI-focused...
Superluminal Medicines joined the ranks of AI-focused biotechs hauling in megarounds, closing an RA Capital-led $120 million Series A, the startup said Monday. The new funds should be sufficient to...
View ArticleTerns’ oral GLP-1 passes Phase 1 test with promising weight loss after one month
Terns Pharmaceuticals unveiled early-phase weight loss data from an oral GLP-1 agonist that it says could be more tolerable at higher doses than currently marketed GLP-1 drugs administered the same...
View ArticleClik here to view.
Relay Therapeutics reports positive PFS data for its PI3Kα inhibitor combo in...
Relay Therapeutics touted positive interim progression-free survival data for its PI3Kα inhibitor in heavily treated breast cancer patients. In the early-stage ReDiscover trial, Relay is investigating...
View ArticleMBX seeks $114M IPO to compete with Ascendis and get a long-acting GLP-1/GIP...
MBX Biosciences is the latest IPO contender after submitting its pitch for a $114 million Nasdaq debut, which will go toward three experimental drugs. The peptide drugmaker is working on treatments for...
View ArticleClik here to view.
Lilly again hires from within for CFO post, elevating 23-year company veteran
The world’s most valuable drugmaker has a new finance chief. Anat Ashkenazi Lucas Montarce stepped into the chief financial officer role at Eli Lilly, effective immediately Monday. He replaces Anat...
View ArticleClik here to view.
Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer,...
Mid-stage clinical trial results show why Merck and Daiichi Sankyo recently moved an antibody-drug conjugate from their $4 billion partnership into Phase 3 studies for an aggressive form of lung...
View ArticleInvestors pour $370M+ into Ken Song's autoimmune biotech after his RayzeBio...
Ken Song knows how to step on the gas pedal. His new company, called Candid Therapeutics, emerged from stealth on Monday morning with more than $370 million to its name and two clinical-stage T cell...
View ArticleBicycle Therapeutics makes an early case for its Padcev competitor: #ESMO24
Bicycle Therapeutics disclosed in an abstract Sunday that 45% of bladder cancer patients responded to its experimental treatment in an early-stage study. In 38 patients evaluated for efficacy, one saw...
View ArticleImmunovant shares mid-stage Graves’ disease data; FDA lifts Rezolute’s hold
Plus, news about Xencor, Bambusa Therapeutics, Grin Therapeutics and Vaxcyte: Immunovant reports Phase 2a Graves’ disease data: Patients taking batoclimab for 12 weeks saw a 76% response rate and an...
View ArticleAstraZeneca's monoclonal antibody misses primary endpoint in mid-stage trial...
AstraZeneca’s anti-IL-33 monoclonal antibody failed a Phase 2a study in chronic obstructive pulmonary disease, though the company noted there were still “encouraging clinical efficacy signals.” In the...
View Article#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and...
On Sunday evening, abstracts from the European Society for Medical Oncology were released. While some of oncology’s most exciting recent data were reported a week before at a separate conference, ESMO...
View ArticleZealand’s GLP-1/GLP-2 drug bounces back with new Phase 1b data
Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist showed promising weight loss in an early-stage trial after a previous effort with lower doses ended with “underwhelming” efficacy. In part one of the...
View ArticleClik here to view.
AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for...
AstraZeneca is focusing on a subgroup of lung cancer patients as it seeks a path to approval for its TROP2-directed antibody-drug conjugate, which earlier this year failed to hit the goal of improving...
View ArticleClik here to view.
GSK says long-acting asthma hopeful significantly cut attacks
GSK said Monday that its projected asthma blockbuster depemokimab reduced asthma attacks by 54% in two large Phase 3 trials, but missed some secondary endpoints. The company teased the results in May,...
View ArticleClik here to view.
CDER chief on inspection backlog: 2025 will be a 'crucial year'
WASHINGTON, DC — CDER director Patrizia Cavazzoni on Monday stressed that while the agency is looking to reduce its backlog of surveillance inspections, pre-approval inspections will continue to...
View ArticleClik here to view.
#WCLC24 roundup: ArriVent thinks its drug can fill Tagrisso's gaps;...
Aside from Summit Therapeutics’ shocking win over Merck’s Keytruda, here’s what else you need to know from the World Conference on Lung Cancer, which is currently underway in San Diego: ArriVent...
View ArticleA General Catalyst-backed startup raised $38M to help workers buy health...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) When Thatch hired its first employees in 2022, none of them were happy with the health insurance plan...
View ArticleHouse passes Biosecure Act, sending Chinese biotech ban to Senate
The US House of Representatives on Monday evening passed the Biosecure Act with broad bipartisan support, advancing a controversial bill that could upend many drugmakers’ supply chains. The bipartisan...
View ArticleFDA advisors question whether Iterum's application for a UTI antibacterial is...
An FDA advisory committee raised concerns Monday about whether Iterum’s application for a new oral antibacterial to treat urinary tract infections is restrictive enough to balance the risk of increased...
View Article